Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
|Corresponding Author||Ruan，Zhihua; Zhang，Yi; Jin，Wenfei|
|Joint first author||Zhou，Jie; Chen，Guanming; Wang，Jiuling|
Anti-PD-1 therapy has shown promising outcomes in the treatment of different types of cancer. It is of fundamental interest to analyze the efficacy of anti-PD-1 therapy in cancer patients infected with hepatitis B virus (HBV) since the comorbidity of HBV and cancer is widely documented. We designed a multicenter retrospective study to evaluate the efficacy of anti-PD-1 therapy on non-liver cancer patients infected with HBV. We found anti-PD-1 therapy achieved much better outcomes in HBV+ non-liver cancer patients than their HBV– counterparts. We performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from esophageal squamous cell carcinoma (ESCC) patients. We found both cytotoxicity score of T cells and MHC score of B cells significantly increased after anti-PD-1 therapy in HBV+ ESCC patients. We also identified CX3CR1 T, a subset of CD8 T, associated with better clinical outcome in HBV+ ESCC patients. Lastly, we found CD8 T from HBV+ ESCC patients showing higher fraction of Exhaustion T than their HBV– counterpart. In summary, anti-PD-1 therapy on HBV+ non-liver cancer patients is safe and achieves better outcomes than that on HBV– non-liver cancer patients, potentially because HBV+ patients had higher fraction of Exhaustion T, which made them more efficiently respond to anti-PD-1 therapy.
共同第一 ; Corresponding
National Natural Science Foundation of China-Yunnan Joint Fund
|WOS Accession No|
Cited Times [WOS]:0
|Document Type||Journal Article|
|Department||School of Life Sciences|
1.Chongqing International Institute for Immunology,Chongqing,400030,China
2.Department of Oncology,Southwest Hospital,Army Medical University,Chongqing,400038,China
3.School of Life Sciences,Southern University of Science and Technology,Shenzhen,518055,China
4.Institute of Immunology,PLA,Army Medical University,Chongqing,400038,China
5.Institute of Cancer,Xinqiao Hospital,Army Medical University,Chongqing,400038,China
6.Pulmonary and Critical Care Medicine,The Third Affiliated Hospital of Chongqing Medical University,Chongqing,400038,China
7.Department of Radiology,Southwest Hospital,Army Medical University,Chongqing,400038,China
8.School of Pharmacy and Bioengineering,Chongqing University of Technology,Chongqing,400054,China
|Corresponding Author Affilication||School of Life Sciences|
Zhou，Jie,Chen，Guanming,Wang，Jiuling,et al. Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer[J]. Oncogenesis,2023,12(1).
Zhou，Jie.,Chen，Guanming.,Wang，Jiuling.,Zhou，Bo.,Sun，Xuemin.,...&Jin，Wenfei.(2023).Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer.Oncogenesis,12(1).
Zhou，Jie,et al."Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer".Oncogenesis 12.1(2023).
|Files in This Item:||There are no files associated with this item.|
|Recommend this item|
|Export to Endnote|
|Export to Excel|
|Export to Csv|
|Similar articles in Google Scholar|
|Similar articles in Baidu Scholar|
|Similar articles in Bing Scholar|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.